HRP20171036T1 - Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c - Google Patents
Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c Download PDFInfo
- Publication number
- HRP20171036T1 HRP20171036T1 HRP20171036TT HRP20171036T HRP20171036T1 HR P20171036 T1 HRP20171036 T1 HR P20171036T1 HR P20171036T T HRP20171036T T HR P20171036TT HR P20171036 T HRP20171036 T HR P20171036T HR P20171036 T1 HRP20171036 T1 HR P20171036T1
- Authority
- HR
- Croatia
- Prior art keywords
- daas
- use according
- patient
- infected
- hcv genotype
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Najmanje dva antivirusna sredstva koja djeluju izravno (DAA) za primjenu u metodi za liječenje HCV infekcije, naznačena time, da navedeni postupak obuhvaća davanje najmanje dva DAA pacijentu koji boluje od HCV infekcije, pri čemu se navedenom pacijentu ne daje interferon niti ribavirin tijekom navedenog liječenja, a navedeni tretman traje 8, 9, 10, 11 ili 12 tjedana, i pri čemu navedeni najmanje dva DAA sadržavaju:
[image]
ili njegove farmaceutski prihvatljive soli, i
[image]
ili njegove farmaceutski prihvatljive soli.
2. Najmanje dva DAA za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da navedeno liječenje traje 12 tjedana.
3. Najmanje dva DAA za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da navedeno liječenje traje 8 tjedana.
4. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran s HCV genotipom 1.
5. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran s HCV genotipom la.
6. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran s HCV genotipom 2.
7. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran s HCV genotipom 3.
8. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran HCV genotipom 4.
9. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran HCV genotipom 5.
10. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je navedeni pacijent inficiran s HCV genotipom 6.
11. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da navedeni pacijent nema cirozu.
12. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da navedeni pacijent ima kompenziranu cirozu.
13. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da navedeni pacijent prije toga nije bio podvrgnut drugom liječenju HCV infekcije.
14. Najmanje dva DAA za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da navedeni pacijent ne reagira na interferon.
15. Najmanje dva DAA za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačena time, da se navedena najmanje dva DAA sastoje od (1) Spoja 1 ili njegove farmaceutski prihvatljive soli i (2) Spoja 2 ili njegova farmaceutski prihvatljiva sol .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783376P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027423 WO2014152514A1 (en) | 2013-03-14 | 2014-03-14 | Combination of two antivirals for treating hepatitis c |
| EP14719977.2A EP2968301B1 (en) | 2013-03-14 | 2014-03-14 | Combination of two antivirals for treating hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171036T1 true HRP20171036T1 (hr) | 2017-10-06 |
Family
ID=50588882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171036TT HRP20171036T1 (hr) | 2013-03-14 | 2014-03-14 | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c |
| HRP20201575TT HRP20201575T1 (hr) | 2013-03-14 | 2020-10-05 | Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201575TT HRP20201575T1 (hr) | 2013-03-14 | 2020-10-05 | Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20140275099A1 (hr) |
| EP (3) | EP3766495A1 (hr) |
| JP (4) | JP6441303B2 (hr) |
| KR (2) | KR20210013344A (hr) |
| CN (2) | CN105073113B (hr) |
| AU (2) | AU2014239563B2 (hr) |
| BR (1) | BR112015023017B1 (hr) |
| CA (1) | CA2901810C (hr) |
| CY (2) | CY1119025T1 (hr) |
| DK (2) | DK3213750T3 (hr) |
| EA (2) | EA033257B1 (hr) |
| ES (2) | ES2624980T3 (hr) |
| HR (2) | HRP20171036T1 (hr) |
| HU (2) | HUE033010T2 (hr) |
| IL (1) | IL240419B (hr) |
| LT (2) | LT3213750T (hr) |
| MX (3) | MX373314B (hr) |
| NZ (2) | NZ631155A (hr) |
| PL (2) | PL2968301T3 (hr) |
| PT (2) | PT2968301T (hr) |
| RS (2) | RS56202B1 (hr) |
| SG (2) | SG11201507364SA (hr) |
| SI (2) | SI3213750T1 (hr) |
| TW (2) | TWI642436B (hr) |
| WO (1) | WO2014152514A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3213750T3 (da) | 2013-03-14 | 2020-10-19 | Abbvie Inc | Kombination af to antivirale midler til behandling af hepatitis c |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| MX2015017953A (es) * | 2013-07-02 | 2016-10-28 | Abbvie Inc | Metodos para tratar el virus de hepatitis c. |
| CN105658219A (zh) * | 2013-10-25 | 2016-06-08 | 艾伯维公司 | 用于治疗hcv的方法 |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| CA2943054A1 (en) * | 2014-04-02 | 2015-10-08 | Abbvie Inc. | Methods for treating hcv |
| MX388482B (es) * | 2014-04-02 | 2025-03-20 | Abbvie Inc | Métodos para tratar el virus de la hepatitis c. |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| HK1250627A1 (zh) * | 2015-06-26 | 2019-01-11 | Abbvie Inc. | 用於治疗hcv的固体药物组合物 |
| US20180177779A1 (en) * | 2015-07-08 | 2018-06-28 | Abbvie Inc. | Methods for Treating HCV |
| US20230385268A1 (en) * | 2022-05-17 | 2023-11-30 | Abbvie Inc. | Methods for Treating HCV |
| EA201890334A1 (ru) * | 2015-07-17 | 2018-06-29 | Эббви Инк. | Твердые фармацевтические композиции для лечения вируса гепатита с |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| JP2019529426A (ja) * | 2016-09-23 | 2019-10-17 | アッヴィ・インコーポレイテッド | 用量調整 |
| CA2994496A1 (en) * | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| WO2019200005A1 (en) * | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| AU2019384793A1 (en) | 2018-11-20 | 2021-06-10 | Abbvie Inc. | Methods for treating acute HCV |
| KR102077833B1 (ko) | 2018-12-10 | 2020-02-14 | 류형준 | 기능성 식품조성물 |
| CN111688355B (zh) | 2019-03-15 | 2022-04-12 | 精工爱普生株式会社 | 液体吸收体、液体吸收器以及液体喷出装置 |
| AU2020271791A1 (en) * | 2019-04-08 | 2021-11-04 | Abbvie Inc. | Solid pharmaceutical compositions for treating HCV |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) * | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| PL2618831T3 (pl) * | 2010-09-21 | 2016-06-30 | Enanta Pharm Inc | Makrocykliczne inhibitory proteazy serynowej HCV pochodzące od proliny |
| US8330139B2 (en) | 2011-03-25 | 2012-12-11 | Micron Technology, Inc. | Multi-level memory cell |
| PH12014500833A1 (en) | 2011-10-21 | 2014-05-26 | Abbvie Inc | Methods for treating hcv |
| EA201490837A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон |
| RU2665365C2 (ru) * | 2012-09-18 | 2018-08-29 | Эббви Инк. | Способы лечения гепатита с |
| DK3213750T3 (da) | 2013-03-14 | 2020-10-19 | Abbvie Inc | Kombination af to antivirale midler til behandling af hepatitis c |
-
2014
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko not_active Withdrawn
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en not_active Ceased
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 HR HRP20171036TT patent/HRP20171036T1/hr unknown
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 MX MX2018008084A patent/MX373314B/es unknown
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active Active
-
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
-
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
-
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
-
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
-
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
-
2020
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
-
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171036T1 (hr) | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c | |
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| JP2014530874A5 (hr) | ||
| JP2016513703A5 (hr) | ||
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| RU2019114665A (ru) | Противовирусные композиции для лечения инфекций, связанных с коронавирусами | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| DE12189198T1 (de) | Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon. | |
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| ME02196B (me) | Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja | |
| JP2013507439A5 (hr) | ||
| HK1199816A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| EA201201235A1 (ru) | Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv | |
| EA201490836A1 (ru) | Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| RU2015114543A (ru) | Способы лечения гепатита с | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| WO2015084741A3 (en) | Methods of treating hepatitis c virus infection in subjects with cirrhosis | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| EA201491525A1 (ru) | Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae | |
| RU2015114566A (ru) | Способы лечения гепатита с | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| HRP20191710T1 (hr) | Postupci za liječenje poremećaja ciklusa uree | |
| HRP20171514T1 (hr) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt |